< Back to Article
Economic evaluation of finotonlimab plus bevacizumab as first-line therapy for advanced hepatocellular carcinoma
Fig 2
Optimal curve fitting extrapolation of two treatment schemes.
A. Simulated PFS curve; B. Simulated OS curve.
doi: https://doi.org/10.1371/journal.pone.0349044.g002